Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER-1: Denufosol in Mild Cystic Fibrosis
NCT00357279Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2006
- Primary completion
- Sep 2008
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Placebo Arm with Denufosol Arm (2 arms). Primary endpoint: Forced Expiratory Volume in 1 second at 48 weeks. Started Jul 2006; status: completed.
02
Drugs
denufosol tetrasodium
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00357279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357279.